What is Chemed Corp's earnings per share (EPS)?

Chemed Corp (CHE) reported diluted earnings per share of $0.02 for fiscal year 2025. This represents a -8.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Chemed Corp Financials

CHE

Trailing 12 months to June 30, 2026

Revenue $2.6B +3.3% YoY

Net Income $10.0M +188.3% YoY

EPS (Diluted) $19.88 +2.3% YoY

Free Cash Flow $323.5M -11.7% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 31, 2026 Currency USD FYE December

Chemed Corp (CHE) reported $2.6B in revenue over the twelve months to Jun 30, 2026, up 3.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CHE FY2025 2026-08-29

Chemed’s dominant mechanic is cash generation supporting substantial shareholder distributions as operating margins and balance-sheet cushion narrow.

Sales expanded from FY2024 to FY2025 while operating margin fell from 15.1% to 13.4%; costs absorbed scale instead of producing greater operating leverage. That combination points to a business whose recent growth has required proportionally heavier operating costs.

Operating cash flow exceeded operating income by 14.8% in FY2025, while capital expenditures rose 26.8% year over year; free cash flow conversion nevertheless remained positive, implying non-cash charges and working-capital timing offset heavier reinvestment.

Share repurchases and dividends totaled 1.4x free cash flow in FY2025, while shares outstanding fell 5.9%; distributions therefore exceeded cash generated after capital spending. Meanwhile, current ratio fell 0.3x and debt-to-equity rose 0.1x, indicating less balance-sheet cushion alongside that policy.

Financial Health Signals

Financial Health Score 64/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Chemed Corp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Chemed Corp has an operating margin of 13.4%, meaning the company retains $13 of operating profit per $100 of revenue. This strong profitability earns a score of 84/100, reflecting efficient cost management and pricing power. This is down from 15.1% the prior year.

Growth

Chemed Corp's revenue grew a modest 4.1% year-over-year to $2.5B. This slow but positive growth earns a score of 53/100.

Leverage

Chemed Corp has a moderate D/E ratio of 0.57. This balance of debt and equity financing earns a leverage score of 57/100.

Liquidity

Chemed Corp's current ratio of 1.05 is below the typical benchmark, resulting in a score of 21/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

Chemed Corp converts 12.9% of revenue into free cash flow ($325.5M). This strong cash generation earns a score of 76/100.

Returns

Chemed Corp earns a strong 0.0% return on equity (ROE), meaning it generates less than $1 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 94/100. This is unchanged from the prior year.

Altman Z-Score Safe

12.42

Chemed Corp scores 12.42, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($6.8B) relative to total liabilities ($558.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

5/8

Chemed Corp passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

N/A

Chemed Corp reported $265K of net income while generating $388.3M in operating cash flow. The ratio between the two is outside the range this page publishes as a per-dollar figure, so both figures are given instead.

Interest Coverage Safe

193.28x

Chemed Corp earns $193.28 in operating income for every $1 of interest expense ($338.2M vs $1.8M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.5B

YoY+4.1%

5Y CAGR+4.0%

10Y CAGR+5.1%

Chemed Corp generated $2.5B in revenue in fiscal year 2025. This represents an increase of 4.1% from the prior year.

EBITDA

$403.1M

YoY-6.2%

5Y CAGR-2.0%

10Y CAGR+6.3%

Chemed Corp's EBITDA was $403.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 6.2% from the prior year.

Net Income

$265K

YoY-12.2%

5Y CAGR-75.8%

10Y CAGR-45.3%

Chemed Corp reported $265K in net income in fiscal year 2025. This represents a decrease of 12.2% from the prior year.

EPS (Diluted)

$0.02

YoY-8.0%

5Y CAGR-75.2%

10Y CAGR-44.3%

Chemed Corp earned $0.02 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 8.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$325.5M

YoY-11.5%

5Y CAGR-5.4%

10Y CAGR+9.8%

Chemed Corp generated $325.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 11.5% from the prior year.

Cash & Debt

$74.5M

YoY-58.2%

5Y CAGR-14.5%

10Y CAGR+17.6%

Chemed Corp held $74.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Dividends Per Share

$2.20

YoY+22.2%

5Y CAGR+10.8%

10Y CAGR+9.1%

Chemed Corp paid $2.20 per share in dividends in fiscal year 2025. This represents an increase of 22.2% from the prior year.

Shares Outstanding

14M

YoY-6.0%

5Y CAGR-3.0%

10Y CAGR-2.1%

Chemed Corp had 14M shares outstanding in fiscal year 2025. This represents a decrease of 6.0% from the prior year.

Margins & Returns

Gross Margin

32.5%

YoY-2.6pp

5Y CAGR-1.2pp

10Y CAGR+3.0pp

Chemed Corp's gross margin was 32.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 2.6 percentage points from the prior year.

Operating Margin

13.4%

YoY-1.7pp

5Y CAGR-5.4pp

10Y CAGR+1.4pp

Chemed Corp's operating margin was 13.4% in fiscal year 2025, reflecting core business profitability. This is down 1.7 percentage points from the prior year.

Net Margin

0.0%

YoY0.0pp

5Y CAGR-15.3pp

10Y CAGR-7.1pp

Chemed Corp's net profit margin was 0.0% in fiscal year 2025, showing the share of revenue converted to profit. That is unchanged from the prior year.

Return on Equity

0.0%

YoY0.0pp

5Y CAGR-35.4pp

10Y CAGR-21.5pp

Chemed Corp's ROE was 0.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. That is unchanged from the prior year.

Capital Allocation

Share Buybacks

$431.5M

YoY+19.4%

5Y CAGR+19.7%

10Y CAGR+21.9%

Chemed Corp spent $431.5M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 19.4% from the prior year.

Capital Expenditures

$62.8M

YoY+26.8%

5Y CAGR+1.3%

10Y CAGR+3.6%

Chemed Corp invested $62.8M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 26.8% from the prior year.

R&D Spending

Not reported for fiscal year 2025.

CHE Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CHE quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	$2.6B	$2.5B+4.1%	$2.4B+7.4%	$2.3B+6.1%	$2.1B-0.2%	$2.1B+2.9%	$2.1B+7.3%	$1.9B+8.7%	$1.8B+7.0%	$1.7B+5.7%	$1.6B+2.2%	$1.5B+6.0%	$1.5B+3.0%	$1.4B-1.2%	$1.4B+5.5%	$1.4B
Cost of Revenue	$1.7B	$1.7B+8.2%	$1.6B+7.6%	$1.5B+7.0%	$1.4B0.0%	$1.4B-0.6%	$1.4B+4.3%	$1.3B+7.6%	$1.2B+6.7%	$1.2B+3.1%	$1.1B+2.6%	$1.1B+5.1%	$1.0B+2.6%	$1.0B-2.4%	$1.0B+6.5%	$970.5M
Gross Profit	$859.3M	$823.2M-3.6%	$854.3M+7.0%	$798.8M+4.4%	$765.1M-0.6%	$769.8M+9.8%	$701.4M+13.6%	$617.4M+11.2%	$555.0M+7.5%	$516.2M+11.9%	$461.4M+1.2%	$455.8M+8.1%	$421.6M+4.2%	$404.5M+2.0%	$396.7M+2.9%	$385.5M
SG&A Expenses	$440.8M	$417.2M-1.7%	$424.4M+7.4%	$395.1M+10.1%	$358.7M-2.2%	$366.7M+11.1%	$330.2M+8.0%	$305.7M+12.7%	$271.2M-2.0%	$276.7M+13.6%	$243.6M+2.4%	$237.8M+6.8%	$222.6M+3.3%	$215.6M+3.3%	$208.7M+3.2%	$202.3M
Operating Income	$349.2M	$338.2M-7.7%	$366.5M+7.6%	$340.6M-0.9%	$343.5M+0.1%	$343.0M-12.0%	$389.7M+51.4%	$257.4M+5.6%	$243.6M+115.5%	$113.0M-36.8%	$178.7M-3.1%	$184.5M+9.5%	$168.4M+26.3%	$133.4M-14.7%	$156.4M+1.8%	$153.7M
Interest Expense	$3.3M	$1.8M-1.7%	$1.8M-42.7%	$3.1M-32.2%	$4.6M+145.4%	$1.9M-20.7%	$2.4M-48.1%	$4.5M-9.1%	$5.0M+16.8%	$4.3M+15.0%	$3.7M+1.9%	$3.6M-55.5%	$8.2M-45.6%	$15.0M+2.1%	$14.7M+6.0%	$13.9M
Income Tax	$94.2M	$90.5M-7.1%	$97.5M+25.2%	$77.9M-2.7%	$80.1M-2.1%	$81.8M+6.8%	$76.5M+83.6%	$41.7M+22.4%	$34.1M+81.7%	$18.7M-72.6%	$68.3M-2.2%	$69.9M+10.1%	$63.4M+36.1%	$46.6M-17.5%	$56.5M+3.6%	$54.6M
Net Income	$10.0M	$265K-12.2%	$302K+10.8%	$273K+9.2%	$250K-7.0%	$269K-99.9%	$319.5M+45.3%	$219.9M+7.0%	$205.5M+109.4%	$98.2M-9.7%	$108.7M-1.4%	$110.3M+11.0%	$99.3M+28.6%	$77.2M-13.5%	$89.3M+3.9%	$86.0M
EPS (Diluted)	$19.88	$0.02-8.0%	$0.02+11.2%	$0.02+8.5%	$0.02-2.4%	$0.02-99.9%	$19.48+46.4%	$13.31+8.8%	$12.23+108.7%	$5.86-9.6%	$6.48+2.4%	$6.33+13.6%	$5.57+33.9%	$4.16-10.0%	$4.62+12.7%	$4.10

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$673.3M+2.4%	$657.5M+2.8%	$639.3M+2.3%	$624.9M+1.0%	$618.8M-4.4%	$646.9M+1.1%	$640.0M+5.6%	$606.2M
Cost of Revenue	$451.8M+2.3%	$441.7M+6.7%	$414.2M-3.2%	$428.0M-1.4%	$434.1M+0.8%	$430.5M+6.1%	$405.9M+2.4%	$396.2M
Gross Profit	$221.5M+2.6%	$215.8M-4.2%	$225.2M+14.4%	$196.9M+6.6%	$184.7M-14.7%	$216.4M-7.6%	$234.1M+11.5%	$210.0M
SG&A Expenses	$115.2M+0.8%	$114.3M+8.4%	$105.5M-0.3%	$105.8M+5.4%	$100.3M-5.0%	$105.6M+1.3%	$104.3M+2.2%	$102.0M
Operating Income	$89.2M+5.5%	$84.6M-16.0%	$100.7M+34.7%	$74.8M+9.8%	$68.1M-28.1%	$94.8M-16.8%	$113.9M+23.6%	$92.2M
Interest Expense	$1.8M+249.4%	$512K-1.7%	$521K+14.0%	$457K+3.2%	$443K+34.7%	$329K-34.1%	$499K+16.9%	$427K
Income Tax	$23.6M+4.8%	$22.5M-21.5%	$28.7M+48.6%	$19.3M+3.7%	$18.6M-22.1%	$23.9M-19.8%	$29.8M+18.0%	$25.3M
Net Income	$67.7M+2.1%	$66.3M+135.2%	-$188.2M-393.0%	$64.2M+22.4%	$52.5M-26.8%	$71.8M+133.9%	-$211.4M-379.0%	$75.8M
EPS (Diluted)	$5.13+6.0%	$4.84-11.2%	$5.45+22.2%	$4.46+24.9%	$3.57-26.5%	$4.86-19.1%	$6.01+20.2%	$5.00

Not reported in any period shown, so not listed: R&D Expenses.

CHE Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CHE quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$1.5B-7.8%	$1.7B0.0%	$1.7B+15.7%	$1.4B+7.4%	$1.3B-6.4%	$1.4B+13.1%	$1.3B+30.0%	$975.5M+6.0%	$920.0M+4.5%	$880.1M+3.3%	$852.3M-0.9%	$859.9M-3.8%	$893.7M+4.0%	$859.6M+8.0%	$795.9M
Current Assets	$302.6M-23.3%	$394.7M-21.2%	$500.8M+83.7%	$272.6M+18.4%	$230.3M-30.1%	$329.4M+72.8%	$190.7M+19.3%	$159.8M-9.2%	$176.0M+3.6%	$169.9M+12.7%	$150.8M-13.6%	$174.6M-22.3%	$224.7M+13.7%	$197.7M+31.1%	$150.8M
Cash & Equivalents	$74.5M-58.2%	$178.3M-32.4%	$264.0M+256.1%	$74.1M+125.3%	$32.9M-79.8%	$162.7M+2541.7%	$6.2M+27.5%	$4.8M-56.6%	$11.1M-27.4%	$15.3M+4.0%	$14.7M+4.2%	$14.1M-83.3%	$84.4M+21.4%	$69.5M+82.6%	$38.1M
Inventory	$7.5M-7.9%	$8.2M-31.7%	$12.0M+16.9%	$10.3M+1.6%	$10.1M+42.5%	$7.1M-4.9%	$7.5M+30.8%	$5.7M+7.0%	$5.3M-7.3%	$5.8M-8.9%	$6.3M+2.4%	$6.2M-8.0%	$6.7M-5.0%	$7.1M-18.6%	$8.7M
Accounts Receivable	$182.6M+6.7%	$171.2M-5.7%	$181.5M+30.2%	$139.4M+1.6%	$137.2M+8.2%	$126.9M-11.8%	$143.8M+20.4%	$119.5M+5.1%	$113.7M-13.9%	$132.0M+24.2%	$106.3M-14.7%	$124.6M+35.8%	$91.8M-1.7%	$93.3M+19.8%	$77.9M
Goodwill	$667.0M0.0%	$666.7M+14.0%	$585.0M+0.6%	$581.3M+0.5%	$578.6M0.0%	$578.6M+0.2%	$577.4M+13.1%	$510.6M+7.1%	$476.9M+1.0%	$472.4M0.0%	$472.3M+1.2%	$466.7M0.0%	$466.9M+0.2%	$465.8M+1.1%	$460.6M
Total Liabilities	$558.8M+1.7%	$549.6M-1.9%	$560.2M-12.9%	$643.3M-10.6%	$719.5M+34.8%	$533.7M-1.5%	$541.7M+41.0%	$384.2M+1.2%	$379.7M+6.7%	$356.0M+5.0%	$339.1M-17.0%	$408.6M-8.1%	$444.8M+9.5%	$406.3M+6.3%	$382.2M
Current Liabilities	$287.1M+0.5%	$285.7M-8.4%	$312.1M+5.0%	$297.2M-1.7%	$302.4M+1.1%	$299.1M+14.1%	$262.2M+36.8%	$191.7M-1.0%	$193.5M+12.6%	$171.8M+0.3%	$171.3M-2.4%	$175.6M-51.8%	$364.0M+132.1%	$156.8M+7.9%	$145.4M
Long-Term Debt	N/A	N/A	N/A	$92.5M-50.0%	$185.0M	N/A	$90.0M+0.9%	$89.2M-2.2%	$91.2M-8.8%	$100.0M+19.4%	$83.8M-40.7%	$141.3M-23.1%	$183.6M+5.0%	$174.9M+4.9%	$166.8M
Total Equity	$979.4M-12.5%	$1.1B+1.0%	$1.1B+38.7%	$798.7M+28.1%	$623.3M-30.8%	$901.2M+24.0%	$726.6M+22.9%	$591.3M+9.4%	$540.4M+3.1%	$524.1M+2.1%	$513.3M+13.7%	$451.4M+0.5%	$448.9M-1.0%	$453.3M+9.6%	$413.7M
Retained Earnings	$3.0B+8.6%	$2.7B+11.2%	$2.4B+11.3%	$2.2B+11.6%	$2.0B+14.3%	$1.7B+20.9%	$1.4B+16.3%	$1.2B+18.0%	$1.0B+8.4%	$958.1M+10.7%	$865.8M+12.3%	$771.2M+12.4%	$686.1M+10.1%	$623.0M+14.0%	$546.8M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$1.6B+2.8%	$1.5B-0.2%	$1.5B-5.3%	$1.6B-5.5%	$1.7B-0.5%	$1.7B+3.5%	$1.7B-5.7%	$1.8B
Current Assets	$291.2M+6.3%	$274.1M-9.4%	$302.6M-23.4%	$395.2M-19.6%	$491.4M-2.2%	$502.4M+27.3%	$394.7M-19.5%	$490.4M
Cash & Equivalents	$40.2M+138.6%	$16.9M-77.4%	$74.5M-42.6%	$129.8M-48.1%	$249.9M+43.7%	$173.9M-2.5%	$178.3M-25.2%	$238.5M
Inventory	$7.6M+5.9%	$7.2M-4.4%	$7.5M-8.4%	$8.2M-9.9%	$9.1M+17.4%	$7.8M-4.9%	$8.2M-17.2%	$9.9M
Accounts Receivable	$188.6M-12.5%	$215.5M+18.0%	$182.6M-15.3%	$215.6M+16.6%	$184.9M-35.3%	$285.9M+67.0%	$171.2M-12.9%	$196.5M
Goodwill	$699.4M+4.9%	$667.0M0.0%	$667.0M0.0%	$667.0M0.0%	$667.0M0.0%	$666.9M0.0%	$666.7M0.0%	$666.9M
Total Liabilities	$749.1M+8.9%	$687.8M+23.1%	$558.8M+2.2%	$546.9M+5.3%	$519.4M-4.7%	$544.8M-0.9%	$549.6M+3.0%	$533.7M
Current Liabilities	$319.8M-0.5%	$321.4M+11.9%	$287.1M-1.7%	$292.0M+10.7%	$263.9M-9.2%	$290.6M+1.7%	$285.7M+7.9%	$264.8M
Long-Term Debt	$140.0M+53.5%	$91.2M	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$830.5M-2.1%	$848.0M-13.4%	$979.4M-9.0%	$1.1B-10.2%	$1.2B+1.4%	$1.2B+5.6%	$1.1B-9.4%	$1.2B
Retained Earnings	$3.1B+2.0%	$3.0B+2.0%	$3.0B+2.4%	$2.9B+2.0%	$2.8B+1.6%	$2.8B+2.4%	$2.7B+3.1%	$2.6B

CHE Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CHE quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	$390.0M	$388.3M-7.0%	$417.5M+26.4%	$330.3M+6.6%	$309.9M+0.4%	$308.6M-36.9%	$489.3M+62.4%	$301.2M+4.9%	$287.1M+76.7%	$162.5M+20.0%	$135.4M-21.1%	$171.5M+55.5%	$110.3M-26.9%	$150.8M+14.5%	$131.8M-24.4%	$174.3M
Capital Expenditures	$66.5M	$62.8M+26.8%	$49.5M-12.9%	$56.9M-0.8%	$57.3M-2.3%	$58.7M-0.3%	$58.8M+11.0%	$53.0M+0.3%	$52.9M-17.8%	$64.3M+61.7%	$39.8M-9.9%	$44.1M+1.3%	$43.6M+48.6%	$29.3M-16.8%	$35.3M+19.1%	$29.6M
Free Cash Flow	$323.5M	$325.5M-11.5%	$368.0M+34.6%	$273.4M+8.3%	$252.6M+1.1%	$249.9M-41.9%	$430.5M+73.4%	$248.2M+6.0%	$234.3M+138.6%	$98.2M+2.7%	$95.6M-24.9%	$127.4M+90.9%	$66.7M-45.1%	$121.5M+25.9%	$96.5M-33.3%	$144.8M
Investing Cash Flow	-$96.2M	-$59.3M+58.8%	-$143.9M-137.3%	-$60.6M-2.1%	-$59.4M-2.8%	-$57.8M+6.2%	-$61.6M+67.7%	-$190.8M-81.3%	-$105.2M-55.6%	-$67.6M-69.6%	-$39.9M+20.8%	-$50.3M	N/A	-$31.3M+23.0%	-$40.7M-19.3%	-$34.1M
Financing Cash Flow	-$503.4M	-$432.8M-20.5%	-$359.2M-350.0%	-$79.8M+61.9%	-$209.3M+45.0%	-$380.6M-40.3%	-$271.2M-148.4%	-$109.2M+42.0%	-$188.2M-90.0%	-$99.1M-4.3%	-$94.9M+21.3%	-$120.6M	N/A	-$104.6M-75.4%	-$59.6M+60.8%	-$152.1M
Dividends Paid	$33.2M	$31.7M+17.0%	$27.1M+15.3%	$23.5M+6.7%	$22.0M0.0%	$22.0M+4.4%	$21.1M+6.5%	$19.8M+6.0%	$18.7M+7.4%	$17.4M+5.7%	$16.4M+5.3%	$15.6M+9.5%	$14.3M+0.8%	$14.1M+8.6%	$13.0M+3.9%	$12.5M
Share Buybacks	$642.9M	$431.5M+19.4%	$361.4M+433.8%	$67.7M-40.9%	$114.5M-80.1%	$576.0M+228.1%	$175.6M+89.6%	$92.6M-41.7%	$158.9M+67.9%	$94.6M-7.5%	$102.3M+72.5%	$59.3M-46.1%	$110.0M+18.4%	$92.9M+53.3%	$60.6M-57.9%	$144.0M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$84.8M-3.9%	$88.2M-33.9%	$133.5M+60.1%	$83.4M-39.8%	$138.6M+323.3%	$32.7M-80.1%	$164.9M+82.2%	$90.5M
Capital Expenditures	$15.5M-9.3%	$17.1M+4.7%	$16.3M-6.6%	$17.5M+10.7%	$15.8M+19.1%	$13.3M+4.1%	$12.8M-31.6%	$18.6M
Free Cash Flow	$69.3M-2.5%	$71.1M-39.3%	$117.2M+77.8%	$65.9M-46.3%	$122.8M+530.9%	$19.5M-87.2%	$152.2M+111.7%	$71.9M
Investing Cash Flow	-$28.2M+25.3%	-$37.8M-136.9%	-$16.0M-12.1%	-$14.2M+8.1%	-$15.5M-13.2%	-$13.7M-9.2%	-$12.5M+32.4%	-$18.5M
Financing Cash Flow	-$33.2M+69.3%	-$108.1M+37.5%	-$172.8M+8.7%	-$189.3M-301.9%	-$47.1M-100.1%	-$23.5M+88.9%	-$212.5M-276.4%	-$56.5M
Dividends Paid	$7.9M-3.6%	$8.2M-3.8%	$8.5M-1.8%	$8.7M+19.9%	$7.2M-1.5%	$7.3M-2.3%	$7.5M+0.1%	$7.5M
Share Buybacks	$97.5M-48.7%	$190.0M+8.9%	$174.6M-3.4%	$180.8M+320.9%	$42.9M+29.3%	$33.2M-84.1%	$209.3M+262.0%	$57.8M

CHE Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

CHE quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	32.5%-2.6pp	35.1%-0.1pp	35.3%-0.6pp	35.8%-0.1pp	36.0%+2.3pp	33.7%+1.9pp	31.9%+0.7pp	31.1%+0.2pp	31.0%+1.7pp	29.3%-0.3pp	29.5%+0.6pp	28.9%+0.3pp	28.6%+0.9pp	27.7%-0.7pp	28.4%
Operating Margin	13.4%-1.7pp	15.1%0.0pp	15.0%-1.0pp	16.1%+0.1pp	16.0%-2.7pp	18.7%+5.5pp	13.3%-0.4pp	13.7%+6.9pp	6.8%-4.6pp	11.3%-0.6pp	11.9%+0.4pp	11.6%+2.1pp	9.4%-1.5pp	10.9%-0.4pp	11.3%
Net Margin	0.0%0.0pp	0.0%0.0pp	0.0%0.0pp	0.0%0.0pp	0.0%-15.3pp	15.4%+4.0pp	11.3%-0.2pp	11.5%+5.6pp	5.9%-1.0pp	6.9%-0.2pp	7.1%+0.3pp	6.8%+1.4pp	5.5%-0.8pp	6.2%-0.1pp	6.3%
Return on Equity	0.0%0.0pp	0.0%0.0pp	0.0%0.0pp	0.0%0.0pp	0.0%-35.4pp	35.4%+5.2pp	30.3%-4.5pp	34.8%+16.6pp	18.2%-2.6pp	20.8%-0.7pp	21.5%-0.5pp	22.0%+4.8pp	17.2%-2.5pp	19.7%-1.1pp	20.8%
Return on Assets	0.0%0.0pp	0.0%0.0pp	0.0%0.0pp	0.0%0.0pp	0.0%-22.2pp	22.3%+4.9pp	17.3%-3.7pp	21.1%+10.4pp	10.7%-1.7pp	12.4%-0.6pp	12.9%+1.4pp	11.6%+2.9pp	8.6%-1.8pp	10.4%-0.4pp	10.8%
Current Ratio	1.05-0.3x	1.38-0.2x	1.60+0.7x	0.92+0.2x	0.76-0.3x	1.10+0.4x	0.73-0.1x	0.83-0.1x	0.91-0.1x	0.99+0.1x	0.88-0.1x	0.99+0.4x	0.62-0.6x	1.26+0.2x	1.04
Debt-to-Equity	0.57+0.1x	0.490.0x	0.51+0.4x	0.12-0.2x	0.30-0.3x	0.59+0.5x	0.120.0x	0.150.0x	0.170.0x	0.190.0x	0.16-0.1x	0.31-0.1x	0.410.0x	0.390.0x	0.40
FCF Margin	12.9%-2.3pp	15.1%+3.0pp	12.1%+0.3pp	11.8%+0.2pp	11.7%-9.0pp	20.7%+7.9pp	12.8%-0.3pp	13.1%+7.2pp	5.9%-0.2pp	6.1%-2.2pp	8.3%+3.7pp	4.6%-4.0pp	8.6%+1.8pp	6.8%-3.9pp	10.7%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	32.9%+0.1pp	32.8%-2.4pp	35.2%+3.7pp	31.5%+1.7pp	29.8%-3.6pp	33.5%-3.1pp	36.6%+1.9pp	34.6%
Operating Margin	13.3%+0.4pp	12.9%-2.9pp	15.7%+3.8pp	12.0%+1.0pp	11.0%-3.6pp	14.6%-3.1pp	17.8%+2.6pp	15.2%
Net Margin	10.1%0.0pp	10.1%+39.5pp	-29.4%-39.7pp	10.3%+1.8pp	8.5%-2.6pp	11.1%+44.1pp	-33.0%-45.5pp	12.5%
Return on Equity	8.2%+0.3pp	7.8%+27.0pp	-19.2%-25.2pp	6.0%+1.6pp	4.4%-1.7pp	6.1%+25.0pp	-18.9%-25.0pp	6.1%
Return on Assets	4.3%0.0pp	4.3%+16.6pp	-12.2%-16.2pp	4.0%+0.9pp	3.1%-1.1pp	4.2%+16.8pp	-12.7%-17.0pp	4.3%
Current Ratio	0.91+0.1x	0.85-0.2x	1.05-0.3x	1.35-0.5x	1.86+0.1x	1.73+0.3x	1.38-0.5x	1.85
Debt-to-Equity	0.17+0.1x	0.11-0.5x	0.57+0.1x	0.51+0.1x	0.430.0x	0.460.0x	0.49+0.1x	0.43
FCF Margin	10.3%-0.5pp	10.8%-7.5pp	18.3%+7.8pp	10.5%-9.3pp	19.8%+16.8pp	3.0%-20.8pp	23.8%+11.9pp	11.9%

Similar Companies

Option Care Health Inc OPCH

$3.6B

Davita Inc DVA

$11.5B

Ensign Group Inc ENSG

$10.1B

Amedisys Inc AMED

$3.3B

Surgery Partners Inc SGRY

$1.8B

Where Chemed Corp Ranks

Frequently Asked Questions

What is Chemed Corp's annual revenue?

Chemed Corp (CHE) reported $2.5B in total revenue for fiscal year 2025. This represents a 4.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Chemed Corp's revenue growing?

Chemed Corp (CHE) revenue grew by 4.1% year-over-year, from $2.4B to $2.5B in fiscal year 2025.

Is Chemed Corp profitable?

Yes, Chemed Corp (CHE) reported a net income of $265K in fiscal year 2025, with a net profit margin of 0.0%.

What is Chemed Corp's EBITDA?

Chemed Corp (CHE) had EBITDA of $403.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Chemed Corp's gross margin?

Chemed Corp (CHE) had a gross margin of 32.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Chemed Corp's operating margin?

Chemed Corp (CHE) had an operating margin of 13.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Chemed Corp's net profit margin?

Chemed Corp (CHE) had a net profit margin of 0.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Chemed Corp pay dividends?

Yes, Chemed Corp (CHE) paid $2.20 per share in dividends during fiscal year 2025.

What is Chemed Corp's return on equity (ROE)?

Chemed Corp (CHE) has a return on equity of 0.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Chemed Corp's free cash flow?

Chemed Corp (CHE) generated $325.5M in free cash flow during fiscal year 2025. This represents a -11.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Chemed Corp's operating cash flow?

Chemed Corp (CHE) generated $388.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Chemed Corp's total assets?

Chemed Corp (CHE) had $1.5B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Chemed Corp's capital expenditures?

Chemed Corp (CHE) invested $62.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Does Chemed Corp buy back shares?

Yes, Chemed Corp (CHE) spent $431.5M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Chemed Corp have outstanding?

Chemed Corp (CHE) had 14M shares outstanding as of fiscal year 2025.

What is Chemed Corp's current ratio?

Chemed Corp (CHE) had a current ratio of 1.05 as of fiscal year 2025, which is considered adequate.

What is Chemed Corp's debt-to-equity ratio?

Chemed Corp (CHE) had a debt-to-equity ratio of 0.57 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Chemed Corp's return on assets (ROA)?

Chemed Corp (CHE) had a return on assets of 0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Chemed Corp's Altman Z-Score?

Chemed Corp (CHE) has an Altman Z-Score of 12.42, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Chemed Corp's Piotroski F-Score?

Chemed Corp (CHE) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Chemed Corp's earnings high quality?

Chemed Corp (CHE) reported $265K of net income while generating $388.3M in operating cash flow. The ratio between the two is outside the range this page publishes as a per-dollar figure, so both figures are given instead. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Chemed Corp cover its interest payments?

Chemed Corp (CHE) has an interest coverage ratio of 193.28x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Chemed Corp?

Chemed Corp (CHE) scores 64 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.